SCHEMBL5351634

SCHEMBL5351634

CC(=O)OCc1cc(CBr)cc(C(C)(C)C)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
CYP3A4 P08684 1/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
IDH1 O75874 1/20 0.36
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
RXRA P19793 2/20 0.33
RXRB P28702 2/20 0.33
RXRG P48443 2/20 0.33
CA2 P00918 1/20 0.33
ELANE P08246 2/20 0.33
CD69 Q07108 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
HMGCR P04035 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19022381 0.84 ALDH1A1 (0.43) ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2
SCHEMBL19022393 0.81 ALDH1A1 (0.43) ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2
SCHEMBL7598524 0.79 ALDH1A1 (0.49) ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2
SCHEMBL348572 0.78 GABRA1 (0.40) ALDH1A1GABRA1GABRB2RAB9ARXRA
SCHEMBL5666942 0.78 ALDH1A1 (0.64) ALDH1A1CYP3A4SMN1; SMN2IDH1RAB9A
SCHEMBL19047492 0.78 ALDH1A1 (0.41) ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2
SCHEMBL19047491 0.78 ALDH1A1 (0.41) ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2
SCHEMBL19060495 0.76 ALDH1A1 (0.39) ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2
SCHEMBL1789187 0.75 GABRA1 (0.46) MEN1KMT2ASMN1; SMN2L3MBTL1GABRA1
SCHEMBL10005902 0.75 ALDH1A1 (0.58) ALDH1A1CYP3A4L3MBTL1IDH1RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7205295-B2 Benzoxazin-3-ones and derivatives thereof as therapeutic agents WARNER-LAMBERT COMPANY LLC (US) 2007-04-17 US disclosed
EP-1569653-A1 BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K Warner-Lambert Company LLC (US) 2005-09-07 EP disclosed
WO-2004052373-A1 BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K WARNER-LAMBERT COMPANY LLC (US) 2004-06-24 WO disclosed
US-20040121996-A1 Benzoxazin-3-ones and derivatives thereof as therapeutic agents BARVIAN NICOLE (US) 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121996-A1 Benzoxazin-3-ones and derivatives thereof as therapeutic agents XDH, HAX1, CYP4X1 ALDH1A1 782/4885CYP3A4 193/4885MEN1 4065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.